Poxel Announces the Availability of a Bond Issue for a Maximum Amount of €2.5 Million

About this update from Poxel Sa

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":256,"url":"https://media.zenfs.com/en/business-wire.com/10b435ff1ee94b97b41cd462ad26cccf"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/u3JoKdw7O6NuLlEj3zRfgQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTUxMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/10b435ff1ee94b97b41cd462ad26cccf","width":480,"height":256}},"lazy":false},{"type":"text","content":"LYON, France, September 29, 2025--(BUSINESS WIRE)--Regulatory News:","length":67,"tagName":"p"},{"type":"text","content":"POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today announces the availability of a bond issue for a maximum amount of €2.5 million to finance its observation period.","length":396,"tagName":"p"},{"type":"text","content":"Poxel and IPF Partners have agreed on the availability of a bond issue for a maximum amount of €2.5 million to finance the issuer's general needs and/or its working capital requirements as part of the judicial reorganization proceedings initiated on August 5, 20251 . This loan follows the announcement made by the Company as part of the operational and financial transition plan initiated by Poxel with the support of IPF Partners, as set out in its press release dated July 29, 20252.","length":490,"tagName":"p"},{"type":"text","content":"The new financing comes from an additional Tranche D under the IPF bond loan. For the time being, it provides for the use of plain vanilla bonds rather than bonds with warrants.","length":177,"tagName":"p"},{"type":"text","content":"The Company has thus made an initial drawdown under this financing facility in the amount of €500,000.","length":102,"tagName":"p"},{"type":"text","content":"The availability of this bond issue will give rise to successive drawdowns conditional on cash requirements of up to a maximum of €2.5 million. The total drawdowns should enable the company to extend its cash horizon until the end of the observation period, excluding renewal, i.e., February 5, 2026.","length":300,"tagName":"p"},{"type":"text","content...

More updates from Poxel Sa